Covalon Technologies Ltd. , an advanced medical technologies company, announced that it has established a distribution channel for its products into Mexico’s advanced wound care and infection management markets.
Through a distribution arrangement with a partner company in Mexico, Covalon will be distributing Covalon-branded products, including Covalon’s CovaWound and ColActive Plus advanced wound care lines and Covalon’s IV Clear and SurgiClear infection management products into Mexico.
“Mexico is a key market for Covalon,” said Brian Pedlar, Covalon’s chief executive officer. “It is one of the largest and most sophisticated healthcare markets in Latin America. Our success in establishing this key distribution channel in Mexico will help drive increased sales of our products into other Latin American countries.”
“We are starting to implement in the vast Latin American market the exact same strategy we have successfully implemented in the Middle East. Interestingly, the large contract awards Covalon recently won in the highly competitive Saudi Arabian market are definitely being noticed by medical thought-leaders in Latin America,” continued Pedlar.
“As we have consistently stated, Mexico is key to accelerating our business as Covalon enters the vast Latin American market,” said John R. Hands, Covalon’s executive vice president. “Covalon’s products are uniquely positioned to address many of the product gaps currently found in the Latin American medical market, especially when one considers the explosion of diabetic-related wounds in the region”.
Covalon has already signed distribution agreements and commenced sales of its products in:
- El Salvador
- Costa Rica
- Puerto Rico
Covalon expects to have its products cleared by the end of 2016 in:
- Dominican Republic
Regulatory clearance in Brazil is expected in 2017.
With over 600 million people in Latin America and significantly higher rates of hospital-acquired infections as compared to the United States, Covalon’s products will provide advanced options for Latin American clinicians to help reduce infections and promote the healing of chronic wounds when used as part of appropriate clinical protocols.
Covalon offers infection management and advanced wound management dressings for both acute and chronic wounds, and is the only provider of a dual antimicrobial silicone adhesive technology used in its IV Clear and SurgiClear brands. Both of these product lines offer superior efficacy in helping to prevent infections and medical adhesive skin injuries, while providing total insertion or incision site visibility to the healthcare provider.
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon’s patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon’s technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more: www.covalon.com.
(Source: Business Wire)